NextCure Enters All-Stock Merger With Avere Therapeutics to Advance Oral IL-23 Inflammatory Disease Pipeline

The Quick Take

• NextCure (NXTC) entered a definitive all-stock merger agreement with Avere Therapeutics targeting IL-23 diseases
• Avere's oral therapy approach targets a $16B+ market currently dominated by injectable biologics
• NXTC shares moved on the announcement as investors balance dilution risk against pipeline potential

NextCure, Inc. (NXTC), a Nasdaq-listed clinical-stage biopharmaceutical company, has entered into a definitive all-stock merger agreement with privately held Avere Therapeutics, which is developing oral therapies targeting interleukin-23 driven inflammatory diseases. IL-23 is one of the most commercially successful cytokine targets in modern immunology—Johnson & Johnson's Tremfya and AbbVie's Skyrizi together generate over $16 billion annually as injectable biologics. Avere's oral formulation strategy targets a persistent patient preference gap, as chronic disease patients overwhelmingly favour oral maintenance therapy over subcutaneous injection regimens.

The all-stock structure means NXTC shareholders absorb dilution in exchange for access to Avere's pipeline, a trade-off that typically receives cautious initial reception before market participants can assess clinical data supporting the acquired asset. Biotech mergers at this stage—where the target is preclinical or early-clinical—are valued primarily on addressable market size, mechanism differentiation, and proximity to human proof-of-concept data. The IL-23 oral therapy category is scientifically credible but unproven at clinical scale, meaning the risk-adjusted value of Avere's assets heavily depends on Phase 1 trial outcomes.

Near-term catalysts include clinical development disclosures for Avere's oral IL-23 candidate, the combined entity's cash position, and NXTC management's post-merger investor guidance. Biotech sector M&A frequently generates follow-on interest from larger strategic acquirers—Pfizer, Eli Lilly, and Merck have all been acquisitive in immunology—and successful NXTC/Avere data could position the combined entity as an attractive acquisition target. Investors should factor both the transformative upside of an oral IL-23 approval and the high binary risk inherent in pre-Phase-2 biotech assets.

Synthesized from 1 source.